Comments
Bal Pharma’s bulk drugs manufacturing unit at Udaipur has commenced commercial production of intermediates and active pharma ingredients. The API products, scheduled to be manufactured in the unit, were developed by the company’s R&D facility at Bangalore but due to ‘capacity constraints’ at its Bangalore facility they could not become commercially viable till now, the company said in a release to the exchanges. The unit is expected to ease the capacity concerns of APIs and intermediates and will cater to the North and North-Eastern markets of the country and also overseas markets, the statement added. To recapitulate, the company has acquired 100 per cent shareholding and management control of Golden Drugs Pvt Ltd, Udaipur, Rajasthan, in March. Shares of Bal Pharma closed flat at ₹80.70 on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.